CYTOKINETICS, INCORPORATED Restricted Cash
CYTOKINETICS, INCORPORATED (CYTK) had Restricted Cash of $3.11 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCash · last filed 2026-08-06
- 2026-06-30: Restricted Cash $3.11M.
- 2026-03-31: Restricted Cash $3.11M.
- 2025-12-31: Restricted Cash $3.11M.
- 2025-09-30: Restricted Cash $3.11M.
| Period end | Restricted Cash |
|---|---|
| 2026-06-30 | $3.11M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $3.11M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $3.11M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $3.11M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.61M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $375.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $375.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $375.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $375.00K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $375.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $375.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $375.00K 10-Q · filed 2023-11-03 |
| 2023-06-30 | $375.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.60M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $1.60M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |